32 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Oct 20
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:49am
is expected to recruit up to twenty-four COVID-19 patients in severe or critical condition and is designed to assess AllocetraTM in combination with standard … to recruit up to twenty-four COVID-19 patients in severe or critical condition, as defined by the U.S. National Institute of Health (NIH), and is designed
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
27 Oct 20
Report of Foreign Private Issuer
8:03am
, and the on-going Phase II investigator-initiated clinical trial, which is expected to recruit up to twenty-four COVID-19 patients in severe or critical condition … to recruit up to twenty-four COVID-19 patients in severe or critical condition, as defined by the U.S. National Institute of Health (NIH), and is designed
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Oct 20
Report of Foreign Private Issuer
9:30am
-initiated, Phase II clinical trial. The trial is expected to recruit up to twenty-four COVID-19 patients in severe or critical condition … -initiated, Phase II clinical trial. The trial is expected to recruit up to twenty-four COVID-19 patients in severe or critical condition, as defined
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
3 Nov 20
Current report (foreign)
9:14am
study, which is expected to recruit up to 160 sepsis patients in four cohorts, and is designed to assess Allocetra™ treatment in combination … as a multi-center, investigator-initiated, Phase II clinical trial. The trial is expected to recruit up to twenty- four COVID-19 patients in severe
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
3 Feb 21
Current Report
7:55am
, Phase II clinical trial. The trial was designed to recruit up to twenty-four COVID-19 patients in severe or critical condition, as defined by the U.S … of the results from the first sixteen (16) patients, the study is now completed and closed and will not recruit additional patients. Twelve (12) patients
6-K
EX-99.1
jnbvedja4xqoa
7 May 20
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
8:01am
6-K
EX-99.1
1eej0 02syu
10 Nov 21
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
8:00am
6-K
EX-99.1
qzqsbppu4r7vb o5u
13 Dec 21
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
8:00am
6-K
EX-99.1
vg2mj0zw5hx68 u6mgzj
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
zi376uglco
19 Aug 19
Report of Foreign Private Issuer
7:31am
6-K
EX-99.1
gckko
22 Sep 21
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
5ourfx
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.1
chprznmio q5h
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.1
34q dgetsg7tye9
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.2
6v0p2a4kkpipnnx
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am